biomarker analysis of olaparib with or without cediranib in mcrpc
Published 3 years ago • 70 plays • Length 5:41Download video MP4
Download video MP3
Similar videos
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
8:53
prognostic biomarkers to guide treatment of mcrpc
-
2:45
biomarker analysis and updated results from propel
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
-
2:48
assessing parp inhibition and brca1/2 as a prognostic biomarker in mcrpc
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
3:33
prophecy trial: ar-v7 ctcs as a biomarker in mcrpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
10:21
profound: olaparib vs enzalutamide or abiraterone for mcrpc with hrr gene alterations
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
3:29
polo: maintenance olaparib in brca1/2 metastatic pancreatic cancer
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
2:12
dr. patel on an analysis of olaparib and cediranib for ovarian cancer
-
3:54
probio: a biomarker driven study in patients with metastatic prostate cancer
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md